Cancer cells may have a fatal weakness to copper toxicity that researchers are now learning to exploit therapeutically. This vulnerability stems from cancer's heightened metabolic demands, which require elevated copper levels but also make malignant cells susceptible to copper overload when protective mechanisms fail. A surprising discovery reveals that penfluridol, an older antipsychotic medication, can weaponize this copper sensitivity against colorectal cancer cells through a previously unknown molecular pathway. The drug works by directly binding to PDPK1, a key enzyme in cellular signaling networks, which then disrupts the phosphorylation of AKT1 - a critical survival protein that cancer cells depend on for growth and resistance to treatment. This molecular cascade ultimately stabilizes CTR1, a copper transporter protein that floods cancer cells with lethal levels of copper, triggering cuproptosis - a newly recognized form of programmed cell death distinct from traditional apoptosis. The mechanism represents a novel intersection between psychiatric pharmacology and cancer biology, suggesting that existing drugs may harbor untapped anticancer potential through unexpected molecular targets. This copper-mediated cell death pathway offers particular promise because it exploits fundamental metabolic differences between healthy and cancerous tissue. Normal cells typically maintain tight copper homeostasis, while cancer cells operate closer to toxic thresholds due to their aggressive metabolism. However, translating these laboratory findings into clinical applications will require extensive safety studies, particularly given penfluridol's known neurological effects. The research adds to growing evidence that cuproptosis could become a viable therapeutic strategy, potentially complementing conventional chemotherapy by attacking cancer through an entirely different vulnerability than DNA damage or immune activation.